JP4828414B2 - インドール酢酸誘導体および薬剤としてのそれらの使用 - Google Patents

インドール酢酸誘導体および薬剤としてのそれらの使用 Download PDF

Info

Publication number
JP4828414B2
JP4828414B2 JP2006513366A JP2006513366A JP4828414B2 JP 4828414 B2 JP4828414 B2 JP 4828414B2 JP 2006513366 A JP2006513366 A JP 2006513366A JP 2006513366 A JP2006513366 A JP 2006513366A JP 4828414 B2 JP4828414 B2 JP 4828414B2
Authority
JP
Japan
Prior art keywords
propoxy
mmol
optionally
alkyl
phenoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2006513366A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006524709A (ja
JP2006524709A5 (https=
Inventor
マー，シン
カンテイン，ルイス−デイビツド
チヨイ，ソーンギユ
クラーク，ロジヤー
ヘンテマン，マーテイン
ルドルフ，ヨアヒム
ラボア，リコ
ツアング，ツオングア
Original Assignee
ニツポネツクス・インコーポレーテツド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ニツポネツクス・インコーポレーテツド filed Critical ニツポネツクス・インコーポレーテツド
Publication of JP2006524709A publication Critical patent/JP2006524709A/ja
Publication of JP2006524709A5 publication Critical patent/JP2006524709A5/ja
Application granted granted Critical
Publication of JP4828414B2 publication Critical patent/JP4828414B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Indole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2006513366A 2003-04-28 2004-04-28 インドール酢酸誘導体および薬剤としてのそれらの使用 Expired - Fee Related JP4828414B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US46614303P 2003-04-28 2003-04-28
US60/466,143 2003-04-28
PCT/US2004/012959 WO2004098498A2 (en) 2003-04-28 2004-04-28 Indole acetic acid derivatives and their use as pharmaceutical agents

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2010261427A Division JP2011063613A (ja) 2003-04-28 2010-11-24 インドール酢酸誘導体および薬剤としてのそれらの使用

Publications (3)

Publication Number Publication Date
JP2006524709A JP2006524709A (ja) 2006-11-02
JP2006524709A5 JP2006524709A5 (https=) 2007-06-14
JP4828414B2 true JP4828414B2 (ja) 2011-11-30

Family

ID=33434943

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2006513366A Expired - Fee Related JP4828414B2 (ja) 2003-04-28 2004-04-28 インドール酢酸誘導体および薬剤としてのそれらの使用
JP2010261427A Pending JP2011063613A (ja) 2003-04-28 2010-11-24 インドール酢酸誘導体および薬剤としてのそれらの使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2010261427A Pending JP2011063613A (ja) 2003-04-28 2010-11-24 インドール酢酸誘導体および薬剤としてのそれらの使用

Country Status (5)

Country Link
US (2) US7592361B2 (https=)
EP (1) EP1620088A4 (https=)
JP (2) JP4828414B2 (https=)
CA (1) CA2523245C (https=)
WO (1) WO2004098498A2 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1630152A4 (en) * 2003-05-30 2009-09-23 Takeda Pharmaceutical CONDENSED CYCLIC COMPOUND
JP4805552B2 (ja) * 2003-05-30 2011-11-02 武田薬品工業株式会社 縮合環化合物
JP4641942B2 (ja) 2003-10-03 2011-03-02 フェーイレン・ナムローゼ・フェンノートシャップ ヒトおよび動物におけるｉｇｆ−１血清レベルの低下と関連した種々の疾患状態の治療用の治療用組成物の製造のための血清中ｉｇｆ−１レベルを増加できる化合物の使用
US7622491B2 (en) * 2004-08-13 2009-11-24 Metabolex Inc. Modulators of PPAR and methods of their preparation
CA2602336A1 (en) 2005-03-31 2006-10-05 Ucb Pharma S.A. Compounds comprising an oxazole or thiazole moiety, processes for making them, and their uses
EP2759533B1 (en) 2011-09-22 2017-08-02 Takeda Pharmaceutical Company Limited Condensed heterocyclic compound
KR101808196B1 (ko) * 2016-01-08 2017-12-14 대한민국(농촌진흥청장) 왕지네 유래 신규 화합물 및 이의 항혈전 용도
CN106702003B (zh) * 2017-02-28 2021-02-12 固安博健生物技术有限公司 Hsdl1在诊治骨肉瘤中的应用
CN117326903B (zh) * 2023-09-27 2025-05-02 常州大学 一种高立体选择性合成n-烷基化吲哚衍生物的方法

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001058893A2 (de) * 2000-02-11 2001-08-16 Merck Patent Gmbh Indol-3-yl-derivate und deren verwendung als integrin-inhibitoren
WO2002018377A1 (en) * 2000-08-29 2002-03-07 Pharmacia Corporation Compounds containing a bicyclic ring system useful as alpha v beta 3 antagonists
JP2002509931A (ja) * 1998-03-31 2002-04-02 ザ インスティテューツ フォア ファーマスーティカル ディスカヴァリー インコーポレイテッド 置換されたインドールアルカノール酸
WO2002060438A1 (en) * 2001-01-29 2002-08-08 3-Dimensional Pharmaceuticals, Inc. Substituted indoles and their use as integrin antagonists
JP2002531398A (ja) * 1998-12-01 2002-09-24 ザ インスティテューツ フォア ファーマスーティカル ディスカヴァリー インコーポレイテッド 置換インドールアルカン酸を用いた、血清グルコースおよびトリグリセリド濃度の低減と、血管形成阻害の方法
WO2003018553A1 (en) * 2001-08-29 2003-03-06 Warner-Lambert Company Llc Oral antidiabetic agents

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996014843A2 (en) * 1994-11-10 1996-05-23 Cor Therapeutics, Inc. Pharmaceutical pyrazole compositions useful as inhibitors of protein kinases
GB9820113D0 (en) * 1998-09-15 1998-11-11 Merck Sharp & Dohme Therapeutic agents
MXPA03000488A (es) * 2000-07-19 2003-06-24 Procter & Gamble Composiciones para el lavado automatico de trastes en forma de gel, metodos de preparacion y uso de las mismas.
US20070208026A1 (en) * 2003-04-07 2007-09-06 Liu Kevin N-Containing Heteroaromatic Compounds As Modulators Of Ppars And Methods Of Treating Metabolic Disorders

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002509931A (ja) * 1998-03-31 2002-04-02 ザ インスティテューツ フォア ファーマスーティカル ディスカヴァリー インコーポレイテッド 置換されたインドールアルカノール酸
JP2002531398A (ja) * 1998-12-01 2002-09-24 ザ インスティテューツ フォア ファーマスーティカル ディスカヴァリー インコーポレイテッド 置換インドールアルカン酸を用いた、血清グルコースおよびトリグリセリド濃度の低減と、血管形成阻害の方法
WO2001058893A2 (de) * 2000-02-11 2001-08-16 Merck Patent Gmbh Indol-3-yl-derivate und deren verwendung als integrin-inhibitoren
WO2002018377A1 (en) * 2000-08-29 2002-03-07 Pharmacia Corporation Compounds containing a bicyclic ring system useful as alpha v beta 3 antagonists
WO2002060438A1 (en) * 2001-01-29 2002-08-08 3-Dimensional Pharmaceuticals, Inc. Substituted indoles and their use as integrin antagonists
WO2003018553A1 (en) * 2001-08-29 2003-03-06 Warner-Lambert Company Llc Oral antidiabetic agents

Also Published As

Publication number Publication date
JP2006524709A (ja) 2006-11-02
JP2011063613A (ja) 2011-03-31
CA2523245A1 (en) 2004-11-18
CA2523245C (en) 2012-03-06
US7592361B2 (en) 2009-09-22
WO2004098498A3 (en) 2005-07-28
EP1620088A2 (en) 2006-02-01
US20090298854A1 (en) 2009-12-03
WO2004098498A2 (en) 2004-11-18
EP1620088A4 (en) 2007-08-29
US20060264486A1 (en) 2006-11-23
US7964622B2 (en) 2011-06-21

Similar Documents

Publication Publication Date Title
JP2011063613A (ja) インドール酢酸誘導体および薬剤としてのそれらの使用
JP4974463B2 (ja) インダン酢酸誘導体ならびに製薬学的薬剤としてのそれらの使用、中間体及び製造方法
AU2001277056B2 (en) N-substituted indoles useful in the treatment of diabetes
JP7365358B2 (ja) ヒトインテグリンα４β７のアンタゴニスト
EP2021327B1 (en) Antidiabetic bicyclic compounds
EP2079467B1 (en) Antidiabetic bicyclic compounds
JP4759517B2 (ja) 肥満症の処置のためのアリールアルキル酸誘導体の製造および使用
WO2006113919A2 (en) Aryl alkyl acid derivatives for and use thereof
WO2004020408A1 (en) Indoles having anti-diabetic activity
WO2004024697A1 (ja) アミン化合物及びその用途
JP2008528628A (ja) 抗糖尿病性二環式化合物
WO2004011446A1 (en) Indane, dihydrobenzofuran, and tetrahydronaphthalene carboxylic acid derivatives and their use as antidiabetics
CZ2004272A3 (cs) Perorální antidiabetická činidla
JP4530668B2 (ja) インダン酢酸誘導体および薬剤としてのそれらの使用
KR101118574B1 (ko) 당뇨병 및 지질 질환 치료용 크로만 카르복시 산 유도체
CA3147471A1 (en) Inhibitors of human atgl
JP2007538102A (ja) 糖尿病の処置に有用な５−アニリノ−４−ヘテロアリールピラゾール誘導体
WO2010141690A2 (en) Indane analogs and use as pharmaceutical agents and process of making
AU2003262984C1 (en) Indoles having anti-diabetic activity
HK1076628B (en) Pheny(alkyl)carboxylic acid derivatives and dionic phenylalkylheterocyclic derivatives and their use as medicines with serum glucose and/or serum lipid lowering activity

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070423

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070423

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20090731

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20100519

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100525

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100810

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100817

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20101025

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20101101

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101124

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20110301

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110701

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20110711

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20110830

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20110914

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140922

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees